fda announcement semaglutide New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Semaglutide Safety Alerts, Recalls &

Evidence for oxidative pathways in the pathogenesis of PD: are antioxidants candidate drugs to ameliorate disease progression

This is not unlike the recent triumphs of gene therapy, as in $3.5 million for a cure of hemophilia that just got FDA approval, but instead of a rare disease we are talking about the most common medical condition in the world

Considering proximal urea cycle disorders in expanded newborn screening

Stephanie Koch (00:04:28): Excellent

This practical support has made split dosing easier to implement but has also drawn criticism from those who argue that compounding pharmacies should not be encouraging unstudied dosing modifications

However, the exact molecular mechanisms responsible for this preserved effect remains unclear